Adult Henoch-Schönlein purpura associated with small cell lung cancer: A case report and review of the literature

XUE-DE ZHANG, SHUAN-YING YANG, WEI LI, ZONG-JUAN MING, YAN-LI HOU, ZE-QUN NIU and YU-PING ZHANG

Department of Respiratory Medicine, The Second Affiliated Hospital, Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China

Received December 12, 2012; Accepted March 14, 2013

DOI: 10.3892/ol.2013.1274

Abstract. The present study reports the case of a 53-year-old male who had been suffering from coughing and the presence of a blood-streaked sputum for >1 month. Chest computed tomography (CT) and a bronchoscopic brush smear were performed. The patient was subsequently diagnosed with small cell lung cancer (limited stage). The patient developed polyarthritis, abdominal pain, diarrhea and a purpuric rash at 14 days post thoracotomy surgery for lung cancer. Henoch-Schönlein purpura (HSP) was diagnosed based on the clinical symptoms. The patient received chemotherapy with steroid therapy, which resulted in complete remission of the HSP.

Introduction

Henoch-Schönlein purpura (HSP), also known as anaphylactoid purpura, is a systemic vasculitis involving the small blood vessels with multiorgan involvement (1). The skin is a major target organ, and the hallmark of HSP is palpable cutaneous purpura; however, other organs, including the joints, gastrointestinal tract and kidneys, may be affected (1). HSP is the most common vasculitic disease of childhood, but may also occur in adults. It was first reported by Heberden in 1801 and the association between purpura and arthritis was first described by Schonlein in 1837 (2). The descriptions of gastrointestinal (GI) involvement and renal involvement were added by Henoch in 1874 and 1899 (2). Although HSP has been recognized for over 100 years (3), the exact cause of HSP is presently unknown, but malignancy may be a causative factor (4-6). The present study reports a rare case of HSP associated with small cell lung cancer. Written informed consent was obtained from the patient's spouse for publication of this case report.

Case report

A 53-year-old male was admitted to The Second Affiliated Hospital of Xi'an Jiaotong University (Shaanxi, China) in August 2011 with symptoms of coughing and a blood-streaked sputum that had persisted for >1 month. The patient was a smoker with a 30 pack-year history of smoking. Chest computed tomography (CT) showed a mass measuring 50x40 mm in the lower lobe of the right lung. A bronchoscopy revealed an obstruction of the right B9 bronchus with a papillary tumor. A bronchoscopic brush smear was suggestive of small cell undifferentiated carcinoma. CT of the abdomen and head was negative and bone scans showed no evidence of potential metastases. Hematological investigations showed a hemoglobin level of 12.4 g/dl, a white blood cell count of 4.6x10^9/l (normal differential) and a platelet level of 209x10^9/l. Liver functions and blood urea nitrogen (BUN) and creatinine levels were all normal, as was the urinalysis. The final oncological diagnosis was of a limited clinical stage (T2N0M0) small cell lung cancer. Adjuvant chemotherapy consisting of cisplatin and VP-16 was initiated, followed by surgical resection. Histological studies showed small cell undifferentiated carcinoma with mediastinal lymph node metastases. The patient developed polyarthritis, abdominal pain and diarrhea, with a purpuric rash on his bilateral lower extremities and buttocks at 14 days post-surgery. The patient was not taking any medication and did not have any food allergies. Minor abdominal tenderness was revealed upon examination. A new set of hematological investigations showed a hemoglobin level of 12.9 g/dl, a white blood cell count of 8.5x10^9/l, a platelet level of 217x10^9/l and an erythrocyte sedimentation rate (ESR) of 28 mm/l h. The C-reactive protein level was 52 mg/l (normal range ≤10 mg/l) and complement components C3 and C4 were measured at 94 mg/dl (normal range 85-193 mg/dl) and 17 mg/dl (normal range 12-36 mg/dl), respectively. The IgA level was recorded as 582 mg/dl (normal range 76-390 mg/dl) and the blood urea nitrogen (11.48 mmol/l), creatinine level and coagulation screen were all normal. Urinalysis revealed proteinuria of 1.52 g/24 h and hematuria of >100 red blood cells per high-power field. The patient's blood pressure was normal. A stool examination for occult blood was positive. The tests for antistreptolysin O, rheumatoid factor (RF), anti-nuclear antibody (ANA), IgG, IgM, antineutrophil cytoplasmic

Correspondence to: Professor Shuan-Ying Yang, Department of Respiratory Medicine, The Second Affiliated Hospital, Medical College of Xi'an Jiaotong University, No. 157 Xi 5 Road, Xi'an, Shaanxi 710004, P.R. China
E-mail: yangshuanying66@163.com

Key words: lung cancer, Henoch-Schönlein purpura, complications
antibody (ANCA) and cryoglobulin were all normal or negative. Tests for the Hepatitis B surface antigen and antibody for human immunodeficiency virus were negative. Skin and renal biopsies were not performed as the patient refused to consent to the procedures.

The patient was consequently diagnosed with HSP. A treatment was administered that consisted of 60 mg prednisolone daily and methylprednisolone pulses combined with cyclophosphamide. The skin rash, abdominal pain and polyarthritis were resolved within two weeks. The patient also received post-operative thoracic radiotherapy (50 Gy in 25 sessions). Chemotherapy was deferred due to a concern for the increased likelihood of BUN and proteinuria associated with the treatment. The proteinuria improved 2 months after the start of steroid treatment. Chest CT revealed a left lung metastasis from the primary carcinoma, therefore, chemotherapy consisting of carboplatin and VP-16 was administered immediately. The proteinuria improved to 147.6 mg/24 h subsequent to one cycle of chemotherapy. The patient continued chemotherapy for a total of 4 cycles until the hematuria had completely resolved and the proteinuria was normal. A liver metastasis was identified by abdominal CT 6 weeks after the 4 cycles of chemotherapy. The patient received interventional therapy for the liver metastasis. The patient’s general condition gradually deteriorated and he succumbed one year and three months subsequent to the procedures.

Discussion

HSP is a multisystem IgA-mediated vasculitis with a self-limited course, which may affect the skin, joints, gastrointestinal tract and kidneys. A likely mechanism behind this involves a process by which the complexes of immunoglobulin A (IgA) and complement component 3 (C3) become deposited on arterioles, capillaries and venules, thus increasing their brittleness and permeability. This is followed by deposits on the skin, joints, gastrointestinal tract, kidneys and other organs, thus causing bleeding and other symptoms. Purpura, arthritis and abdominal pain are known as the ‘classic triad’ of HSP. HSP occurs more often in children than in adults. The outcome of HSP predominantly depends on the degree of renal involvement.

The diagnosis of HSP is based on the combination of the symptoms, as few other diseases cause the same symptoms together. The diagnostic criteria for HSP, according to the American College of Rheumatology, are palpable purpura, bowel angina, a patient age of <20 years and histological changes of leukocytoclastic vasculitis. A diagnosis of HSP is 87.1% sensitive and 87.7% specific when two or more of these criteria are present (7). The present study patient had palpable purpura of the lower extremities and buttocks combined with bowel angina, thereby meeting the American College of Rheumatology criteria for the diagnosis of HSP. Additionally, the patient had arthritis and hematuria and an increased serum IgA, which provided further support for the diagnosis of HSP.

The exact etiology of HSP is unknown, but factors including bacterial infection or drugs, foods, allergens (8) and autoimmune connective tissue disease (9,10) have been documented. In the literature, associations between solid organ malignancies and HSP have been reported in cases when there were no known triggering factors (11). Several studies have reported the correlation between HSP and malignancies, including esophageal, lung, breast, gastric and prostate cancer, and hematological malignancies (11-13). Solid tumors are more common than hematological malignancies in association with HSP (15). Lung cancer is the most common solid malignancy associated with HSP. In the study by Zurada et al (15), 3 patients with HSP had underlying malignancies, among which solid tumors accounted for 61% and lung cancer accounted for 25%. To the best of our knowledge, 13 cases of HSP associated with lung cancer have been reported to date (Table I) (16-27). In these 13 cases there were 12 male patients and one female patient with an average age of 65.7 years (50-79 years). These cases included 8 diagnoses of squamous cell carcinoma, 3 of adenocarcinoma and 2 of small cell lung cancer. In 6 cases, the onset of the HSP and lung cancer processes was synchronous. In 6 cases, HSP preceded lung cancer and in 1 case HSP occurred after lung cancer had been diagnosed. All 13 patients exhibited skin and kidney involvement, 7 patients had gastrointestinal symptoms and 9 patients had joint involvement. These studies aided in the confirmation of the correlation between lung cancer and HSP. The patient in the present study had no correlation with these pathogenic factors. The onset of HSP occurred 14 days after surgical resection, making it likely that the HSP was associated with the lung cancer.

In the 13 literature cases, the treatment for HSP ranged from oral steroids to a combination of intravenous methylprednisolone followed by prednisone. Other possible regimens include steroids/azathioprine, and intravenous immunoglobulin (IVIG). Although an explicit treatment for HSP associated with lung cancer has not been identified, several studies have presented a treatment for HSP associated with lung cancer. The lung cancer therapies induced a complete remission of HSP in 4 cases (16,17,22,13) while steroid hormones were required for an improvement in HSP in another 6 patients (18,21,24-27). Only one case (18) reported a recurrence of HSP. The patient in the present study initially received prednisolone and methylprednisolone pulses combined with cyclophosphamide. This treatment achieved a partial remission of the HSP with the proteinuria decreased to 668.25 mg/24 h. Following this, a total of 4 cycles of chemotherapy were performed to treat the left lung metastasis. Complete remission of the HSP was achieved, suggesting that the treatment for malignancy may contribute to a complete remission of HSP.

The exact correlation between HSP and malignancies remains somewhat unclear. It is possible that malignancies and HSP in patients may be correlated with the generation and expression of tumor-associated antigens. These antigens, as heterologous material, are able to stimulate the body to produce aberrant antibodies. These antibodies react to antigens and lead to the resultant immune complex deposition within vessel walls. Moreover, tumor-associated antigens reduce the clearance of circulating immune complexes (28,29). In addition, tumor-associated antigens may cause dysfunctionality in lymphocytes and lead to the immunoglobulin subtypes shifting from IgM to IgA.. Once this happens, a large number of inflammatory cytokines may be released and vascular inflammation may eventually occur (30). The treatment of malignant tumors may also cause the occurrence of HSP. It is possible
Table I. Characteristics of patients with Henoch-Schönlein purpura (HSP) associated with lung cancer.

| First author (Ref.) | Age (years)/gender | Histology | Onset of HSP in relation to lung cancer | Organ involvement | Treatment for HSP | Response to treatment | Treatment for lung cancer |
|---------------------|--------------------|-----------|----------------------------------------|-------------------|------------------|----------------------|--------------------------|
| Cairns (16)         | 63/M               | Squamous  | 8 months prior                         | Skin, renal, joint| Not performed    | Remission            | Not performed            |
|                     | 73/M               | Squamous  | Synchronous\(^a\)                      | Skin, renal, joint, GI tract | Not performed    | Remission            | Surgery                  |
| Maurice (17)        | 59/M               | Squamous  | Synchronous                            | Skin, renal, joint | Not performed    | Remission            | Surgery                  |
| Mitchell (18)       | 57/M               | Squamous  | 22 months prior                        | Skin, renal, GI tract | Prednisone and azathioprine | Remission            | Surgery                  |
| Pfitzenmey (19)     | 79/M               | Squamous  | 6 months prior                         | Skin, renal       | Not performed    | Not mentioned        | Not performed            |
| Gutiérrez (20)      | 78/M               | Squamous  | Synchronous                            | Skin, renal, GI tract, joint | Not available | Not mentioned        | Not available            |
| Frigui (21)         | 50/M               | Squamous  | 6 months prior                         | Skin, renal, GI tract, joint | Methylprednisolone and prednisone | Remission            | Chemotherapy, irradiation |
| Blanco (22)         | 67/M               | Small cell| Synchronous                            | Skin, renal       | Not performed    | Remission            | Chemotherapy             |
| Ponge (23)          | 75/M               | Small cell| 8 months prior                         | Skin, renal, joint | Not performed    | Remission            | Chemotherapy             |
| Weiler-Bisig (24)   | 63/M               | Adenocarcinoma | Synchronous                           | Skin, renal, GI tract | Prednisone GI tract | Remission            | Chemotherapy             |
| Solans-Laqué (25)   | 58/M               | Adenocarcinoma | Synchronous                           | Skin, renal, GI tract, joint | Prednisone and γ-globulins | Remission            | Surgery                  |
| Mifune (26)         | 61/M               | Adenocarcinoma | Synchronous                           | Skin, renal, GI tract, joint | Prednisone | Remission            | Chemotherapy             |
| Podjasek (27)       | 71/F               | Squamous  | 3 months after                         | Skin, joint       | Prednisone       | Remission            | Surgery, chemotherapy, irradiation |

\(^a\)Occurred within 1 month of each other. M, male; F, female; GI, gastrointestinal.
that radiotherapy, chemotherapy and surgical resection change the surface antigens of tumor cells or that tumor-associated antigens are released within the tumor cells following their destruction (31). It has previously been demonstrated that numerous chemotherapeutic agents, including erlotinib (32), cytarabine (33) and anastrozole (34), result in HSP.

The patient in the present study developed HSP following surgical resection, however, the exact nature of the correlation between HSP and lung cancer in this case remains poorly defined. The patient did not receive any medication and no known food allergens were consumed. It was therefore postulated that the occurrence of HSP in this patient may have been attributed to the malignancy itself. We suggest that the tumor-associated antigen may have changed or that there may have been internal antigen exposure to the blood circulation during surgical resection, thus leading to the occurrence of HSP.

The present study presents a rare case of HSP associated with small cell lung cancer. To the best of our knowledge, this case is only the third patient with HSP presenting with small cell lung cancer. In addition, this appears to be the only case of HSP occurring post-surgery. Although the present study only involved 1 case, a review of the literature also aided in the confirmation of a correlation between lung cancer and HSP. The present study also suggested that the tumor-associated antigen may change in the treatment process of cancer and lead to the occurrence of HSP. The specific mechanisms by which this occurs will require further research in the future. It remains unclear which is the most efficient treatment for HSP associated with malignant tumors, and since corticosteroid therapy may not cause complete remission, future anti-tumor therapies may play a more crucial role in the treatment of such patients.

References

1. Jennette JC, Falk RJ, Andrassy K, *et al.*: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37: 187-192, 1994.
2. Gedalia A: Henoch-Schönlein purpura. Curr Rheumatol Rep 6: 195-202, 2004.
3. Saulsbury FT: Henoch-Schönlein purpura. Pediatr Dermatol 1: 195-201, 1984.
4. Greer JM, Longley S, Edwards NL, *et al.*: Vasculitis associated with malignancy. Experience with 13 patients and literature review. Medicine (Baltimore) 67: 220-230, 1988.
5. Fain O, Hamidou M, Cacoub P, *et al.*: Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum 57: 1473-1480, 2007.
6. Ng JP, Murphy J, Chalmers EM, *et al.*: Henoch-Schönlein purpura and Hodgkin's disease. Postgrad Med J 64: 881-882, 1988.
7. Mills JA, Michel BA, Bloch DA, *et al.*: The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum 33: 1114-1121, 1990.
8. Kraft DM, Mkeee D and Scott C: Henoch-Schönlein purpura: a review. Am Fam Physician 58: 405-408, 1998.
9. Garber ME, Mohr BW and Calabrese LH: Henoch-Schönlein purpura associated with anti-Ro (SSA) and antiphospholipid antibody syndrome. J Rheumatol 20: 1964-1966, 1993.
10. Al-Attrach I, Al-Shibli A, Al-Riyami L, *et al.*: Systemic lupus erythematosus with severe nephritis that mimicked Henoch-Schoenlein purpura. Arab J Nephrol Transplant 4: 159-161, 2011.
11. Mitsui H, Shibagakl N, Kawamura T, *et al.*: A clinical study of Henoch-Schönlein Purpura associated with malignancy. J Eur Acad Dermatol Venereol 23: 394-401, 2009.
12. Purtuset E, Lion E, Launay-Russ, E, *et al.*: Adult Henoch-Schönlein purpura associated with malignancy. Semin Arthritis Rheum 29: 360-367, 2000.
13. Watts RA, Lane S and Scott DG: What is known about the epidemiology of the vasculitides? Best Pract Res Clin Rheumatol 19: 471-478, 2005.
14. Flynn AN, du Prey B, Al Ardati H, *et al.*: Adult-onset malignancy-associated Henoch-Schönlein purpura. Scan J Rheumatol 40: 325-326, 2011.
15. Zurada JM, Ward KM and Grossman ME: Henoch-Schönlein purpura associated with malignancy in adults. J Am Acad Dermatol 55 (5 Suppl); 65-70, 2006.
16. Cairns SA, Mallick NP, Lawler W and Williams G: Squamous cell carcinoma of bronchus presenting with Henoch-Schönlein purpura. Br Med J 2: 474-475, 1978.
17. Maurice TR: Carcinoma of bronchus presenting with Henoch-Schönlein purpura. Br Med J 2: 831, 1978.
18. Mitchell DM and Hoffbrand BI: Relapse of Henoch-Schönlein disease associated with lung carcinoma. J R Soc Med 72: 614-615, 1979.
19. Pitzenmeyer P, Besancenot JF, Brichton P, *et al.*: The association of bronchial carcinoma and rheumatoid purpura. Ann Med Interne (Paris) 140: 423-424, 1989 (In French).
20. Gutiérrez Maciás A, Alonso Alonso J, Sanz C and Aguirre Ferrasti C: Schönlein-Henoch purpura and epidermoid carcinoma of the lung. Rev Clin Esp 191: 282-283, 1992 (In Spanish).
21. Freguiu M, Kechacht M, BenHmida M, *et al.*: Adult-Schönlein-Henoch purpura associated with epidermoid carcinoma of the lung. Nephrol Ther 5: 201-204, 2009 (In French).
22. Blanco R, González-Gay MA, Ibáñez D, *et al.*: Henoch-Schönlein purpura as a clinical presentation of small cell lung cancer. Clin Exp Rheumatol 15: 545-547, 1997.
23. Ponce T, Boutouille D, Moreau A, *et al.*: Systemic vasculitis in a patient with small-cell neuroendocrine bronchial cancer. Eur Respir J 12: 1228-1229, 1998.
24. Weiler-Bisig D, Ettlin G, Brink T, *et al.*: Henoch-Schönlein purpura associated with esophagus carcinoma and adenocarcinoma of the lung. Clin Nephrol 63: 302-304, 2005.
25. Solans-Laqué R, Bosch-Gil JA, Pérez-Bocanegra C, *et al.*: Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases. J Rheumatol 35: 294-304, 2008.
26. Mitjane D, Watanabe S, Kondo R, *et al.*: Henoch Schöenlein purpura associated with pulmonary adenocarcinoma. J Med Case Rep 5: 226, 2011.
27. Podjasek JO, Wetter DA, Pittelkow MR, *et al.*: Henoch-Schönlein purpura associated with solid-organ malignancies: three case reports and a literature review. Acta Derm Venereol, 92: 388-392, 2012.
28. Sánchez-Guerrero J, Gutiérrez-Ureña S, Vidallier A, *et al.*: Vasculitis as a paraneoplastic syndrome. Report of 11 cases and review of the literature. J Rheumatol 17: 1458-1462, 1990.
29. Fortin PK: Vasculitides associated with malignancy. Curr Opin Rheumatol 8: 30-33, 1996.
30. Hayem G, Gomez MJ, Grossin M, *et al.*: Systemic vasculitis and epithelioma. A report of three cases with a literature review. Rev Rhum Engl Ed 64: 816-824, 1997.
31. Hughes RA, Bottomley DM, Keat AC and Drury A: Henoch-Schönlein purpura occurring in association with carcinoma of the breast. Eur J Med 2: 310-312, 1993.
32. Yuba T, Nagata K, Shiotus S, *et al.*: Henoch-Schönlein purpura induced by erlotinib (Tarceva): a case report. Nihon Kokyuki Gakkai Zasshi 48: 81-85, 2010 (In Japanese).
33. Aktas B, Topcuoglu P, Kurt OK, *et al.*: Severe Henoch-Schönlein purpura induced by cytarabine. Ann Pharmacother 43: 792-793, 2009.
34. Conti-Beltramini M, Pagnani O, Ballerini G, *et al.*: Henoch-Schönlein purpura (HSP) during treatment with anastrozole. Ann Oncol 18: 205-207, 2007.